The American Heart Association (AHA), along with the American College of Cardiology (ACC), has released the 2026 Guideline on the Management of Dyslipidemia. This is the first update since the 2018 cholesterol guidelines and focuses on dyslipidemias, including LDL (bad) cholesterol and triglycerides. The update was jointly published in the journal Circulation and the Journal of the American College of Cardiology. The recent guideline is retitled the 2026 Guideline on the Management of Dyslipidemia and incorporates evidence up to late 2024. It emphasises lifetime cardiovascular risk reduction through earlier screening and personalised therapy to reduce the rising heart disease in younger populations.

Dr. Roger Blumenthal, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, said, "We know 80% or more of cardiovascular disease is preventable and elevated LDL cholesterol, sometimes referred to as 'bad' cholesterol, is a major part of that risk. While we want to try to optimise healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimisation, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago. And lower LDL cholesterol for longer, just like lower blood pressure for longer, results in much greater protection against future heart attack and stroke risk."

The New Guidelines

The older risk scores like the Pooled Cohort Equations overestimated the 10-year risk of a heart attack and stroke by 40%-50%. The recent guideline moves from the old pooled cohort equations to the AHA PREVENT-ASCVD risk calculator for prevention decisions. These have been categorised as:

Less than 3 per cent: Low
3-5%: Borderline
5-10%: Intermediate
10% or higher: High

Source: NDTV - March 15,2026